Biohaven Ltd

In a Stage 2 advancing medium-term context under a broader long-term downtrend, BHVN has pulled back into its rising 9/21 EMA zone and is tightly tracking above both EMAs with neutral RSI and Options Score, indicating limited exhaustion. The speculative strategy's focus on clear structural setups supports immediate participation on this reclaim, while mindful of Stage 2→3 transition risk.

• ↑Q4 revenue $463M, +627% YoY, driven by NERTEC ODT popularity.
• ↑Pfizer partnership provides $1.24B upfront plus milestones, boosting cash and global reach.
• ↓Valuation premium poses risk if sales growth decelerates.